Media

Cellix Bio Pharma, a global contract research organization (CRO), transforms today’s healthcare challenges into tomorrow’s solutions
Download Brochure

Cellix Bio Pharma Milestones

Hyderabad, 06-March-2020- Cellix Bio Pharma

Cellix Bio Pharma Completes the Acquisition of Avaca Pharma

HYDERABAD, India--(BUSINESS WIRE), August 04, 2020 06:30 PM

Cellix Bio Pharma completes the acquisition of Avaca Pharma, a formulation development company. Avaca Pharma services include discovery, formulation development, regulatory support, and product development activities..

The acquisition of Avaca Pharma provides Cellix Bio Pharma with world-class expertise in NME/NCE discovery R&D services and a unique and extensive set of high-content and complex formulations. Combined with Cellix Bio’s established small molecule discovery and drug development capabilities, this expansion uniquely positions Cellix Bio Pharma as a leading provider of integrated R&D services across large and small molecule platforms a base for further expansion.

With a vision of an innovative approach of execution, exceptional customer service, and focus on providing value, Cellix Bio Pharma is delighted to offer expanded leading-edge service solutions.

Avaca Pharma Research and Development Centre (RDC) at IDA Pashamylaram, Hyderabad, has a total high-quality, compliant space of 6000 sq. ft. in a 1.2-acre location, of which Formulation R&D occupies 3000 sq. ft. and Analytical Operations, 3000 sq. ft., with provisions for expansion.

Avaca Pharma Commercial Operations Centre (COC) is located between Hyderabad and Vijayawada, Andhra Pradesh. The new planned construction will host commercial manufacturing, packaging, analytical, and warehousing facilities within the 14 acres environmentally friendly campus. The facility will have a total built-up cGMP space of 126,685 sq.ft. meeting regulatory compliance standards.

Read More
Cellix Bio Pharma Completes the Acquisition of avaca Pharma

Cellix Bio Pharma Completes the Acquisition of Avaca Pharma

Hyderabad, 03-August-2020

Cellix Bio Pharma completes the acquisition of Avaca Pharma, a formulation development company. Avaca Pharma services include discovery, formulation development, regulatory support, and product development activities.

The acquisition of Avaca Pharma provides Cellix Bio Pharma with world-class expertise in NME/NCE discovery R&D services and a unique and extensive set of high-content and complex formulations. Combined with Cellix Bio’s established small molecule discovery and drug development capabilities, this expansion uniquely position Cellix Bio Pharma as a leading provider of integrated R&D services across both large and small molecule platforms and provides a base for further expansion.

With a vision of an innovative approach of execution, exceptional customer service, and focus on providing value, Cellix Bio Pharma is delighted to offer expanded leading-edge service solutions.

Avaca Pharma Research and Development Centre (RDC) at IDA Pashamylaram, Hyderabad, has a total high-quality compliant space of 6000 Sq. ft. in a 1.2-acre location, of which Formulation R&D occupies 3000 sq. ft. and Analytical Operations 3000 sq. ft. with provisions for expansion.

Avaca Pharma Commercial Operations Centre (COC) is located between Hyderabad and Vijayawada, Andhra Pradesh, and the new planned construction will host commercial manufacturing, packaging, analytical, and warehousing facilities within the 14 acres environmentally friendly campus. The facility will have a total built up cGMP space of 126,685 sq.ft. meeting regulatory compliance standards.

Hyderabad, 06-March-2020- Cellix Bio Pharma
Capabilities

Cellix Bio Pharma Initiates Acquisition of Avaca Pharma: Formulation Development CRO

Hyderabad, 06-March-2020

Cellix Bio Pharma initiates the acquisition of Avaca Pharma, a formulation development CRO. Avaca Pharma services include discovery, formulation development, regulatory support, and product development activities.

The acquisition of Avaca Pharma provides Cellix Bio Pharma with world-class expertise in NME/NCE discovery R&D services and a unique and extensive set of high-content and complex formulations. Combined with Cellix Bio’s established small molecule discovery and development capabilities, this expansion uniquely position Cellix Bio Pharma as a leading provider of integrated R&D services across both large and small molecule platforms and provides a base for further expansion.

With a shared vision of an innovative approach to execution, exceptional customer service, and focus on providing value, Cellix Bio Pharma is delighted to offer expanded leading-edge service solutions to our clients.

About Cellix Bio

Cellix Bio Pharma is a wholly owned subsidiary of Cellix Bio.

Cellix Bio is an innovative biopharmaceutical company focused on the development of innovative technologies that have the potential to make a significant medical and commercial impact with value driven clinical outcomes. Cellix Bio works closely with the scientific community, universities and research institutions to advance and build the value of Synergix AITM technology, develop the most promising intellectual property, and create value for its stakeholders and investors. Cellix Bio has a robust pipeline of new medicines addressing unmet medical needs across diverse therapeutic areas including neurology, ophthalmic, dermatology, oncology, inflammation and metabolic diseases. More information on Cellix Bio can be found at www.cellixbio.com

About Avaca Pharma

Avaca Pharma is a new-gen pharmaceutical development and commercialization organization with a vision to innovate for better health. Rooted in integrity, technical acumen, customer service and reliability, our organizational goal is to thrive for the best patient outcome. Avaca Pharma is vested in bringing quality pharmaceutical products with a patient centric approach. More information on Avaca Pharma can be found at www.avacapharma.com

Read More